The Call for Late-Breaking Clinical Trials submissions for ACC.08 is now closed. Notification of all acceptances will be provided the week of Jan. 28, 2008.

General Information

• These sessions provide notable exposure and recognition for studies likely to significantly affect clinical practice. Potential presenters must complete an online application outlining the purpose, design, and methods of the study. Evaluation for presentation in the Late-Breaking Clinical Trial sessions will be based on the impact and novelty of the research; rigor of the design/methods; major clinical endpoints; and the quality of the statistical plan. Priority will be given to trials whose results will be presented for the first time at ACC.08 and SCAI-ACCi2.
• Investigators need not be ACC or SCAI members to participate.
• The program directors will decide the meeting forum for LBCTs that are accepted for presentation (either ACC.08 or SCAI-ACCi2).  
• There is a $100 non-refundable processing fee for each late-breaking application submitted payable online by credit card only.
• No reimbursement for travel, hotel or per diem expenses will be give to ACC.08/SCAI-ACCi2 faculty and presenters. The registration fee is waived for accepted late-breaking presenters; however, a registration form must be completed to obtain a hotel reservation and meeting badge. If you have not already registered, click here to register today.  If you have already registered and paid the registration fee, please request a refund in writing, by sending an email to dkimelma@acc.org.
• Notification will be sent to the person who submitted the application with final disposition information during the week of Jan. 28, 2008.
• General information subject to change due to circumstances beyond the ACC’s control.

Policies

1. Applications must be SUBMITTED BY 11:59 p.m. CENTRAL STANDARD TIME ON MONDAY, JANUARY 7, 2008. The meeting organizers are not responsible for submissions which are not submitted by this deadline date.
2. Submissions with system status of “incomplete” cannot be processed.
3. Submission of an application constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the meeting, if not justified, will jeopardize future acceptance of applications.
4. There is no limit to the number of applications an investigator may submit. If selected, the presenter must be one of the co-authors listed.
5. Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected.
6. Follow all instructions for completing the submission. Be sure to structure the content into Background, Methods, Results, and Conclusion (if known) sections.
7. Clarity of expression will be considered in the review process. The overall quality of language used should assure comprehension by the reader.
8. Use a maximum of five unique abbreviations in the body of the application. No abbreviations should appear in the title. Place abbreviations in parentheses after the full word the first time it appears. Abbreviations increase the difficulty of reading and evaluating applications, which will be considered in the review process.
9. If authors' names appear on more than one application, their names must appear and be spelled identically on each application in order to facilitate proper indexing. Whenever possible, do not list authors with initials only.
10. Any abstract presenting data that in whole or part is contained in a Late-Breaking Clinical Trial submission that was submitted in September for presentation in the general program cannot be presented in the regular program and must be withdrawn if that trial is accepted for presentation as a Late-Breaking Trial. Please notify Kristin Turner kturner@acc.org or Heidi Hopper hhopper@acc.org if another abstract based on the clinical trial was submitted via the regular abstract submission process and needs to be withdrawn.
11. After the deadline, the system will be closed, and submissions will be forwarded for the reviewing process. An author may not revise or resubmit an application in order to make changes or corrections after the deadline. Proofread applications carefully to avoid errors before they are submitted. ACC is not authorized to make changes to a submission. If you choose to withdraw an application after the submission deadline, this request must be received by ACC in writing. Please notify Kristin Turner kturner@acc.org or Heidi Hopper hhopper@acc.org.
12. Applications are not eligible for consideration if the data has been presented at a U.S. or international meeting held before the ACC.08/SCAI-ACCi2 meetings.
13. Applications are not eligible for consideration if the data have been published before the ACC.08/SCAI-ACCi2 meetings.
14. Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association.
15. The ACC.08 and SCAI-ACCi2 Program Committees endorse the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.
16. Each presenting author will be asked to comply with the American College of Cardiology Foundation (ACCF) “Statement of Disclosure (Vested Interest) and Conflict of Interest for Accredited Educational Activities” Policy. Indication of the relationship, the associated commercial entity and level of support is required for each author at the time of submission. Again this year, all presenters at ACC.08/SCAi-ACCi2 must display a slide at the beginning of their presentation indicating disclosure information as applicable, or that they have nothing to disclose.
17. The submitter acts on behalf of all co-authors and in submitting an application, transfers to ACCF and the Society for Cardiovascular Angiography and Interventions (SCAI) the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following: a) all proprietary rights other than copyright, such as patent rights; and b) the right to use all or part of the application in future works of their own. The meeting organizers, as holder of the copyright on the accepted application, reserve all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.
18. In light of increased attention to the manner in which research results (particularly those affecting the stock of publicly-traded companies) are made public, ACCF is clarifying its policies and procedures governing the disclosure of scientific results contained in late-breaking clinical trial presentations and abstracts. All authors must read and comply with the ACCF embargo policy. Anyone determined by ACCF to have violated the embargo policies may be withdrawn from the program or sanctioned as deemed necessary. Click here for the complete ACCF Embargo Policies document.
    

• All applications submitted are disclosed to members of the peer review selection committee, as well as to ACC/F employees and contractors as necessary in connection with the annual meeting. Those applications that are accepted for presentation are summarized for publication after the Annual Scientific Session and are not publicly available to the public in advance of the meetings.  Applications not accepted for presentation are not summarized, and are ordinarily not disclosed outside of ACCF and persons associated with the selection process (i.e., the peer review committee). Notwithstanding these policies and procedures, ACCF is not subject to any confidentiality requirements with respect to submitted applications. In addition, compliance with any disclosure or nondisclosure requirements that apply to researchers or research sponsors (whether under federal securities laws, contract agreement, or otherwise) is the sole responsibility of the researcher and/or sponsor, and not the ACCF.
• All authors, presenters, company sponsors, attendees, journalists and/or anyone with knowledge of embargoed content must comply with ACC embargo policies, which state that scientific study results presented during the Annual Scientific Session must not be released publicly prior to the time of presentation at ACC.08 or the ACC-sponsored press conference, whichever comes first.
• Some, though not all, LBCTs may be selected for an ACC press conference. LBCTs not selected for a press conference remain under embargo until the time of the presentation.
• Presentation or discussion of scientific research results at satellite meetings or press conferences prior to the scheduled Annual Scientific Session scientific presentation is strictly forbidden.
• In the event that media representatives contact authors, presenters and/or company sponsors, any information must be given with the understanding that scientific research results are to remain under embargo until the time of presentation or ACC-sponsored press conference. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters and/or company sponsors.
• Authors, presenters, company sponsors, attendees, journalists and/or anyone with knowledge of embargoed content must seek prior ACC approval before publicly revealing any embargoed content for any reason. The ACC leadership, press staff and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., SEC requirements) must be met or in the case of public health concerns.